Lexeo Therapeutics, Inc. Debt Securities, Available-for-sale
Lexeo Therapeutics, Inc. (LXEO) had Debt Securities, Available-for-sale of $141.34 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale $141.34M.
- 2026-03-31: Debt Securities, Available-for-sale $155.78M.
- 2025-12-31: Debt Securities, Available-for-sale $183.57M.
- 2025-09-30: Debt Securities, Available-for-sale $81.77M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $141.34M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $155.78M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $183.57M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $81.77M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $117.03M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $77.95M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $93.52M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |